Reducing Time To First-In-Human Trials With Robotic Sterile Fill-Finish Manufacturing Services

Small and emerging biopharma companies are taking over early-phase drug development, which means there's a greater need for faster clinical trials and secure manufacturing processes. Robotic gloveless isolator sterile fill-finish (SFF) systems are being used to address these challenges.

In a discussion with Pharma’s Almanac Editor in Chief David Alvaro, Ph.D., experts from PCI Pharma Services — Jerome Detreille, Derek Truninger, and Peter Kim — explain how their innovative robotic SFF technology supports accelerated timelines and reduces manufacturing risks for their client partners. They highlight the significant advantages of robotic SFF, such as improved sterility, reduced risk of contamination, and streamlined processes, which ultimately help speed up the progression to first-in-human trials and subsequent funding rounds.

As biopharma companies increasingly adopt advanced drug delivery solutions like prefilled syringes and auto-injectors, PCI Pharma Services positions itself as a crucial partner in navigating these complex developments and ensuring the successful, timely advancement of therapeutic candidates.